Posted on June 2, 2015 by Gray Connections
by H. Jack West, MD The hot subject at ASCO this year was immunotherapy for many cancers, and developments in lung cancer led the charge. The specific findings of greatest interest were that the PD-1 inhibitor Opdivo (nivolumab) was found to have a far superior survival, higher response rate, and overall better side effect profile than Taxotere (docetaxel) as second line treatment after initial chemotherapy. The US FDA approved Opdivo for squamous NSCLC, and we anticipate an approval for non-squamous NSCLC soon. But there are still several open questions as we integrate… Read More
Posted on May 18, 2015 by Gray Connections
Lung cancer patient advocates are beginning to make their voices heard and gain acceptance in the medical world. For the first time ever, patient advocates will be speaking from the stage at the World Conference on Lung Cancer (WCLC), the largest meeting dedicated to lung cancer anywhere. The meeting, which runs September 6-9 in Denver and is sponsored by the International Association for the Study of Lung Cancer (IASLC), will have sessions on research, treatment, biotech developments…and patient advocacy topics. In the session titled “Advocacy in Practice,” #LCSM Comoderator Janet Freeman-Daily will… Read More
Posted on May 3, 2015 by Gray Connections
Lung cancer patients, caregivers, advocates and healthcare providers may sometimes feel overwhelmed by diagnosis, treatment (or lack thereof), and published statistics for lung cancer, the top cancer killer. In reality, we have more reasons to have HOPE now than ever before. More effective treatment options have been approved for lung cancer during the past five years than in the past four decades. Molecular and genomic testing identifies patients who can take targeted therapies. Early detection with low dose CT screening is now covered by insurance. Research into new biomarkers, immunotherapies, and… Read More
#LCSM 
You must be logged in to post a comment.